Terbium-161 DOTATATE for metastatic gastro‑enteropancreatic neuroendocrine tumors
Official title: Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors: Assessment of Safety and Efficacy
Run by Tata Memorial Hospital · NCT07404176 · Data updated 2026-11-12
This trial tests terbium-161 DOTATATE, a targeted radioactive drug, in adults with metastatic well-differentiated GEP‑NETs who have progressed after lutetium‑177 therapy.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | radiation |
| Locations | 2 sites (Mumbai, Maharashtra and 1 other locations) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | February 28, 2028 |
| Study ends | February 28, 2029 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT07404176 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with histologically confirmed well‑differentiated GEP‑NETs, Ga‑68 DOTANOC PET/CT Krenning score ≥3, metastatic or inoperable disease, prior progression after Lu‑177 DOTATATE, adequate organ function, and ECOG ≤2 are ideal candidates.
✕Probably not a fit
Patients with poor organ function (significant renal impairment or cytopenias), concurrent malignancies, pregnancy or lactation, or somatostatin receptor‑negative tumors are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional trial gives terbium‑161 labeled to DOTATATE (a somatostatin analogue) to patients with somatostatin receptor–positive metastatic well‑differentiated gastro‑enteropancreatic neuroendocrine tumors. Eligible participants are identified by Ga‑68 DOTANOC PET/CT with Krenning score ≥3 and typically have progressed after prior Lu‑177 DOTATATE PRRT. Participants receive the radiopharmaceutical and are monitored for safety, organ function, and anti‑tumor activity using imaging and clinical assessments. The study is being conducted at Tata Memorial Hospital and ACTREC in the Mumbai metropolitan area to gather preliminary efficacy and safety data for this isotope.
Why it matters
Potential benefit: If successful, terbium‑161 DOTATATE could provide an effective PRRT option when Lu‑177 is limited and may improve tumor cell kill due to its Auger electron emissions.
How similar studies have gone: PRRT with Lu‑177 DOTATATE has proven benefit in NETTER trials, but clinical data specifically supporting terbium‑161 in patients are limited and largely based on preclinical rationale and early exploratory work.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, age greater than 18 years * Histopathological diagnosis of well-differentiated GEP-NET * Positive Ga-68-DOTANOC PET/CT, Krennings score \>/=3 * Locally advanced/inoperable disease or metastatic disease * Patient who have shown disease progression with Lu-177 DOTATATE PRRT * Karnofsky performance-status score of at least 60 or ECOG performance status \</=2 * Life expectancy greater than 6 months Exclusion Criteria: * Serum creatinine level of more than 1.6 mg/dl or a creatinine clearance of less than 50 ml/min * Hemoglobin level of less than 8.0 g per deciliter * Red blood cell count less than 300,000/cubic millimeter * White cell count of less than 2000 per cubic millimeter * Platelet count of less than 75,000 per cubic millimetre * Total bilirubin level of more than 3 times the upper limit of the normal range * Serum albumin level \> 3.0 g/dl * Pregnancy and Lactation * Patients with concurrent malignancies
Where it's running
-
Tata Memorial Hospital, Mumbai, India
Mumbai, Maharashtra, India Recruiting -
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
Navi Mumbai, Maharashtra, India Recruiting
Study contacts
- Principal investigator: Ameya Puranik, DNB — Tata Memorial Hospital, Mumbai
- Study coordinator: Ameya Puranik, DNB
- Email: ameya2812@gmail.com
- Phone: +919619811125
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans
A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.
-
CTX-471 for NCAM-positive metastatic neuroendocrine tumors
A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.
-
Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors
This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.
-
Safety and tolerability of NEUK203-13 CAR-NK cells for DLL3 in advanced neuroendocrine tumors
This early phase trial tests NEUK203-13, an off-the-shelf CAR-NK cell therapy, in adults with advanced SCLC or other neuroendocrine tumors to see if it is safe and if it shows any anti-tumor activity.
-
Cabozantinib for adults with previously treated neuroendocrine tumors
This study will see how cabozantinib works and how safe it is for adults with neuroendocrine tumors that have continued to grow after prior systemic treatment.
-
Surufatinib for adults with advanced neuroendocrine neoplasms in routine care
This study will see if daily oral surufatinib, given alone or with other treatments, helps adults with advanced neuroendocrine tumors when used in regular clinical practice.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.